Recent Updates
Recently added Catalysts
ENTA Positive Sentiment

Zelicapavir Reduces Symptom Duration and Hospitalization in a Randomized, Double-Blind, Placebo-Controlled, International, Phase 2 Trial

Tuesday, May 19, 2026 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: The Phase 2 trial of Zelicapavir demonstrated a significant reduction in symptom duration and hospitalization rates for patients. Conducted internationally with a randomized, double-blind, placebo-controlled design, the study highlights the potential benefits of this treatment. These findings could have important implications for managing related viral infections.
Price reaction · baseline $13.45 (2026-05-18 close) · hit pre-market · clean, no other ENTA news in the window
day 0 close · peak
+2.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Zelicapavir shows promise in reducing symptom duration.
  • The trial was well-structured as a randomized, double-blind study.
  • Results indicate potential for reduced hospitalization rates.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~63 mo
Minimal dilution risk
Lead asset
EDP-235
Phase 2 · COVID-19

Full Press Release Details

• About About Us Management Team Board of Directors Timeline
• Pipeline Overview Hepatitis C Virus Respiratory Syncytial Virus SARS-CoV-2 Immunology KIT Inhibition STAT6 Inhibition MRGPRX2
• Science Overview Publications
• Patients Overview Clinical Trials Expanded Access Policy Resources
• Careers Join Us Culture Core Values Testimonials Benefits
• Collaborations Partnering
• Investors Overview Press Releases Events & Presentations Stock Information Stock Quote & Chart Historic Price Lookup Investment Calculator Analyst Coverage Financials Quartlery Results Annual Reports SEC Filings Corporate Responsibility Overview Environmental Social Governance Investor Resources Investor FAQs RSS Feed 2026 Annual Meeting Email Alerts
• Contact Us
• About Us
• Management Team
• Board of Directors
• Timeline
• Overview
• Hepatitis C Virus
• Respiratory Syncytial Virus
• SARS-CoV-2
• Immunology KIT Inhibition STAT6 Inhibition MRGPRX2
• KIT Inhibition
• STAT6 Inhibition
• MRGPRX2
• Overview
• Publications
• Overview
• Clinical Trials
• Expanded Access Policy
• Resources
• Join Us
• Culture
• Core Values
• Testimonials
• Benefits
• Partnering
• Overview
• Press Releases
• Events & Presentations
• Stock Information Stock Quote & Chart Historic Price Lookup Investment Calculator Analyst Coverage
• Financials Quartlery Results Annual Reports SEC Filings
• Corporate Responsibility Overview Environmental Social Governance
• Investor Resources Investor FAQs RSS Feed
• 2026 Annual Meeting
• Email Alerts
• Stock Quote & Chart
• Historic Price Lookup
• Investment Calculator
• Analyst Coverage
• Quartlery Results
• Annual Reports
• SEC Filings
• Overview
• Environmental
• Social
• Governance
• Investor FAQs
• RSS Feed
• Print Page Print Page
• Email Alerts Email Alerts
• RSS Feeds RSS Feeds
• Contact IR Contact IR

Frequently Asked Questions

What is Zelicapavir?

Zelicapavir is a treatment being evaluated for its effectiveness in reducing symptoms of viral infections.

What were the results of the Phase 2 trial?

The trial showed that Zelicapavir significantly reduced symptom duration and hospitalization rates.

What type of study was conducted for Zelicapavir?

The study was a randomized, double-blind, placebo-controlled trial.

What implications do the trial results have?

The results suggest that Zelicapavir could be beneficial in managing viral infections.

ShareAdd on Google
Tags: ENTA Viatris Investor Conferences Healthcare Zelicapavir Phase 2 hospitalization symptom duration
Last updated: May 19, 2026

Biotech snapshot

Cash runway
$211M liquidity · $3M/mo burn
~63 mo
Minimal dilution risk
Lead asset
EDP-235Phase 2
COVID-19 →